Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 1/18/24 → 1/18/26 |
Funding
- Intellia Therapeutics Incorporated: $48,295.00
MAGNITUDE: A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with ATTR-CM
- Anaya, Paul (PI)